US Markets

Elanco Animal Health wins approval to buy Bayer unit

Credit: REUTERS/Wolfgang Rattay

Elanco Animal Health has won U.S. antitrust approval to buy Bayer AG's animal health business on condition that it sell assets to treat three ailments, two in dogs and one in cattle, the Federal Trade Commission said on Wednesday.

Adds background on deal, other approvals

WASHINGTON, July 15 (Reuters) - Elanco Animal Health ELAN.N has won U.S. antitrust approval to buy Bayer AG's BAYGn.DE animal health business on condition that it sell assets to treat three ailments, two in dogs and one in cattle, the Federal Trade Commission said on Wednesday.

The deal was valued at $7.6 billion when it was announced in August 2019.

To win antitrust approval, the FTC said it required the companies to sell assets related to oral treatments to kill fleas on dogs, an inflammation of dogs' inner ears and some pour-on cattle insecticides which control multiple insects.

The deal won EU antitrust approval in June.

It would create the world's second largest animal health company, with analysts expecting the $44 billion animal health sector to grow 5%-6% per year, driven by an increase in livestock farming and spending on pets.

The FTC said that Elanco agreed to sell its canine ear medicine Osurnia to Dechra Pharmaceuticals PLC, its dog flea medicine Capstar to PetIQ Inc and its cattle pour-on insecticide treatment StandGuard to Neogen Corp.

(Reporting by Diane Bartz Editing by Chizu Nomiyama)

((Diane.Bartz@thomsonreuters.com; 1 202 898 8313;))

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

In This Story

ELAN NEOG PETQ

Latest US Markets Videos

Test Video TOPIC US market

Nov 24, 2021

Reuters

Reuters, the news and media division of Thomson Reuters, is the world’s largest international multimedia news provider reaching more than one billion people every day. Reuters provides trusted business, financial, national, and international news to professionals via Thomson Reuters desktops, the world's media organizations, and directly to consumers at Reuters.com and via Reuters TV.

Learn More